New drug applications approved by US FDA as of 16 - 31 August 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Hepatology - Malaysia digital copy today!
Treatment with nidufexor led to significantly reduced serum alanine aminotransferase (ALT) levels and hepatic fat fraction in patients with nonalcoholic steatohepatitis (NASH), according to a phase II study presented at ILC 2020.
A trivalent vaccine against hepatitis (hep B) is safe and effectively elicits robust immune response compared with a monovalent Hep B vaccine, according to the PROTECT and CONSTANT studies presented during the 2020 digital ILC.